Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials.

"Declarations Ethics approval and consent to participateThis study was approved by the Ethics Committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine. The procedures used in this study adhere to the tenets of the Declaration of Helsinki (as revised in 2013). Consent for publicationNot applicable. Competing interestsJiao Zhang and Ying Yang are employees of Genecast Biotechnology Co., Ltd. Xiang Lin and Xiaoyu Zhu are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other disclosures were reported. Competing interests Jiao Zhang and Ying Yang are employees of Genecast Biotechnology Co., Ltd. Xiang Lin and Xiaoyu Zhu are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. No other disclosures were reported."

"Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81972167, No. 82172869, No.82002419), Shanghai Shenkang Hospital Development Center (No. SHDC12019133, No. SHDC2022CRT012), the Science and Technology Commission of Shanghai Municipality (No. 21XD1423200), Clinical Research foundation of Shanghai Pulmonary Hospital (No. FKLY20008), Shanghai Sailing Program (No. 20YF1427900) and Shanghai Innovative Collaboration Project (No. 2020CXJQ02). The funding sources didn’t have any involvement in the study design; the collection, analysis and interpretation of data; the writing of the report; and the decision to submit the article for publication."

"Trial registration: The patients were from two registered clinical trials (ClinicalTrials.gov: NCT02535507, NCT02834936)."